


iScience, Volume 25

Supplemental information

**IL11 stimulates ERK/P90RSK to inhibit LKB1/AMPK
and activate mTOR initiating a mesenchymal
program in stromal, epithelial, and cancer cells**

Anissa A. Widjaja, Sivakumar Viswanathan, Joyce Goh Wei Ting, Jessie Tan, Shamini G. Shekeran, David Carling, Wei-Wen Lim, and Stuart A. Cook






Figure S2. Secretion of IL11 and MMP2 from human cardiac fibroblasts is dependent on ERK activity, Related to Figure 1. (A-B) Secreted (A) IL11 or (B) MMP2 from human cardiac fibroblasts stimulated with (A) HyperIL11 or (B) IL11 in the absence or presence of U0126. All conditions were carried out in the presence of 0.1% DMSO. Data are shown as box-and-whisker with median (middle line), 25th–75th percentiles (box) and min-max percentiles (whiskers); one-way ANOVA with Tukey’s correction (n=4 biological replicates); ****p<0.0001. BL: Baseline




Figure S3. A549 cells express IL11RA, Related to Figure 1. Immunofluorescence image of IL11RA expression in A549 cells (representative dataset from n=3 biological replicates, scale bar, 100 μ m).




Figure S4. Optimal MOI determination for Ad-WT-LKB1 and Ad-DM-LKB1(S325A/S428A) in A549 cells, Related to Figure 1. Western blots of LKB1 and GAPDH following transduction with either adenovirus encoding empty vector (Null), wild-type (WT)-LKB1, or double mutant (DM)-LKB1 at an MOI of 5, 10 or 20 with incubation period of either 2 or 24 hours in A549 cells (n=1 biological replicate).




Figure S5. Sequential phosphorylation of LKB1 by ERK and P90RSK, Related to Figure 1. WB of total ERK, P90RSK, AMPK, mTOR, P70S6K and S6RP in IL11(10ng/ml)-stimulated A549 cells infected with adenovirus encoding WT-LKB1 across time. Experiments were conducted concurrently with **Figure 1F** (n=2 biological replicates).



A**B**

Figure S6. IL11 inhibits LKB1/AMPK signalling in ERK-dependent manner in LKB-expressing lung epithelial cancer cell line (H1792), Related to Figure 1. (A-B) WB of phospho and total ERK, P90RSK, LKB1, AMPK, mTOR, P70S6K and S6RP in IL11(10ng/ml)-stimulated H1792 cells (A) over a time course (n=2 biological replicates) and (B) in the presence of U0126 (10 μ M), a MEK inhibitor at a 2-hour time point (n=3 biological replicates).




Figure S7. Optimal MOI determination for Ad-WT-LKB1 and Ad-DM-LKB1(S325A/S428A) in HSCs, Related to Figure 2. Western blots of LKB1 and GAPDH following transduction with either adenovirus encoding empty vector (Null), WT-LKB1, or DM-LKB1 at an MOI of 5, 10 or 20 with incubation period of either 2 or 24 hours in HSCs (n=1 biological replicate).




Figure S8. AMPK activation inhibits IL11-driven hepatotoxicity, Related to Figure 3. ALT concentrations in the supernatant of hepatocytes stimulated with IL11 (10 ng/ml, 24 hours) in the presence of DMSO, metformin (1 mM), AICAR (1 mM) or 991 (1 μ M); one-way ANOVA with Dunnett's correction. Data are shown as box-and-whisker with median (middle line), 25th–75th percentiles (box) and min-max percentiles (whiskers) (n=4 biological replicates); ****p<0.0001.




Figure S9. IL11/ERK activity inhibits LKB1/AMPK to cause renal tubular epithelial cell dedifferentiation, Related to Figure 3. WB of p- and total ERK, P90RSK, LKB1, AMPK, ACC, mTOR, P70S6K, S6RP, SNAI1, E-Cadherin, αSMA and GAPDH in TECs stimulated with IL11 (10 ng/ml) in the presence of U0126 (10 μM) or DMSO (n=3 biological replicates).

















Figure S10. IL11 stimulates hepatocyte SNAI1 expression, Related to Figure 3. WB of SNAI1 and GAPDH in hepatocytes stimulated with IL11 (10 ng/ml) or palmitate in the presence of IgG, X203, or X209 (2 μ g/ml) (n=2 biological replicates)


Data S2. Densitometry analyses, Related to STAR Methods.

1B**1C****1F****1G**


1G**1H**

2A**2B****2C****2F**


2F




2I




3A





3B




3C




3F




3K





4A




4B








S6A




S6B





S10



Data S3. Uncropped blots, Related to STAR Methods.

Figure 1A



Figure 1B




Figure 1C




Figure 1F




Figure 1G




Figure 1H




Figure 2A




Figure 2B




Figure 2C




Figure 2F




Figure 2I




Figure 3A




Figure 3B




Figure 3C




Figure 3F




Figure 3K




Figure 4A




Figure 4B




Figure 4C




Figure S1A




Figure S4




Figure S5




Figure S6A







Figure S6B**Figure S7****Figure S9****Figure S10**